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a b s t r a c t
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Introduction
Brain disorders, including Alzheimer's disease (AD), often involve specific early alterations in the metabolism of glucose in the brain (Mosconi, 2005; Teune et al., 2010) . The idea of alleviating symptoms of dementia by boosting cerebral energy metabolism has been toyed with for decades (Branconnier, 1983 ), yet safe pharmacological agents with well characterized mechanism of action are still lacking. In this sense, we have investigated here the local cerebral glucoregulatory potential of the endocannabinoid system in rodents.
The endocannabinoid system mainly consists of two established (CB 1 and CB 2 ) receptors that are activated by endocannabinoid signalling molecules, such as N-arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) (Di Marzo and De Petrocellis, 2012; Pertwee, 2012) . At the cellular level, endocannabinoid signalling via CB 1 receptors (CB 1 Rs) regulates peripheral energy metabolism and glucose uptake (Matias et al., 2008) . In the brain, acute activation of the psychoactive CB 1 R inhibits mitochondrial respiration and glucose metabolism in neurons and astrocytes, without robust effect on the uptake of glucose (B enard et al., 2012; Duarte et al., 2012; Lemos et al., 2012) . Similarly, the peripheral glucoregulatory role of the non-psychoactive CB 2 receptors (CB 2 Rs) has also been recognized (Agudo et al., 2010; Romero-Zerbo et al., 2012) , although this remains to be documented in the brain.
CB 2 Rs were first described in peripheral organs and cells (Gali egue et al., 1995) , and subsequently in activated microglial cells (Carlisle et al., 2002) -the resident immune cell of the brain. However, during the last decade, the presence and function of CB 2 Rs have been described in other cell types in the brain. An early evidence was provided by Van Sickle et al. (2005) who identified and functionally characterized CB 2 Rs in brainstem neurons. Other studies have reported CB 2 R involvement in neurogenesis, axon guidance, and neuronal excitability (Den Boon et al., 2012; Duff et al., 2013; Sierra et al., 2014; Zhang et al., 2014) . Furthermore, astrocytes (in particular, activated astrocytes) are also endowed with CB 2 R (Sheng et al., 2005; Benito et al., 2008; Bari et al., 2011; Rodríguez-Cueto et al., 2014) . However, a recent report added that the vast majority of specific CB 2 R immunoreactivity in the healthy mouse neocortex is neuronal (Savonenko et al., 2015) . Nonetheless, conventional CB 2 R immunstaining techniques may have possible limitations (Ashton, 2011) . Therefore, it is important that the highly sensitive and specific RNAscope technique also proved the presence of CB 2 R mRNA in excitatory and inhibitory neurons (but hardly in resting microglia) throughout the hippocampus of adult mice (Li and Kim, 2015) . Furthermore, these hippocampal (and medial entorhinal) CB 2 Rs appear to control the synaptic release of GABA (Morgan et al., 2009; And o et al., 2012) , and the deletion of CB 2 Rs is associated with impaired synaptic plasticity at excitatory synapses, too, in the mouse hippocampus (Li and Kim, 2016a) . Not surprisingly, the CB 2 R KO mice exhibit memory impairments as well (Li and Kim, 2016b) .
Besides these indefinite physiological roles, the therapeutic potential of central CB 2 Rs have also been recognized. There is an increasing clinical interest in endorsing novel selective CB 2 R agonists to treat different illnesses (Atwood and Mackie, 2010; Pertwee, 2012; Han et al., 2013) , including AD. Indeed, prolonged oral treatment with a CB 2 R selective agonist conferred antiinflammatory effects and reduced microglial activation, which have been demonstrated to mitigate the cognitive deficits of TgAPP mice (Martín-Moreno et al., 2012) . Similarly, subchronic treatment with another CB 2 R agonist promoted b-amyloid (Ab) clearance, and restored synaptic plasticity, cognition, and memory in Ab injected rats (Wu et al., 2013) . These results were extended in other reports using TgAPP/PS1 mice (Aso and Ferrer, 2014; Cheng et al., 2014) . Additionally, the severity of Ab pathology correlates positively with the density of the CB 2 R rather than the CB 1 R (Esposito et al., 2007; Solas et al., 2013; Savonenko et al., 2015) . Therefore, to map the putative glucoregulatory potential of CB 2 Rs in healthy mice and in a model of b-amyloidosis, we have taken advantage of recently optimized in vitro and in vivo protocols (Lemos et al., 2012; Martín-Moreno et al., 2012) . Here we report that acute CB 2 R activation increases glucose uptake in the brain of young and middle-aged mice both in vitro and in vivo, which highlights a novel cerebral role for the CB 2 R with therapeutic potential.
Materials and methods

Chemicals
substances and 2-NBDG were reconstituted in DMSO at 1000Â the final concentration, and stored in aliquots at À20 C.
Animals
All studies were carried out in accordance with the EU (2010/63/ EU) and FELASA guidelines, and they were approved by the Spanish and Portuguese Ministries of Agriculture, as well as the local institutional Animal Care Committees (license No. 280279-31-A and 025781). All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals McGrath et al., 2010) . A total of 73 animals were used in the experiments described here.
For the experiments which are summarized in Figs. 3AB, 4 and 5, we used 12-month-old (middle-aged) C57Bl/6j mice (i.e. wild type [WT] littermates as controls), and 12-month-old C57Bl/6j transgenic 2576 mice, containing the human APP695 transgene with mutations at KM670/671NL (hereafter, TgAPP mice). TgAPP mice have b-amyloid-burden but no evident cell loss (Hsiao et al., 1996) .
At 12 months, TgAPP mice did not differ in weight from the WT C57Bl/6j mice (WT: 39.6 ± 2.4 g; TgAPP: 38.6 ± 2.3 g), yet they displayed compromised new object recognition compared to WT mice (data not shown). Data shown in Fig. 3C were obtained from 10-week-old male WT CD-1 mice and their CB1R global KO littermates (Ledent et al., 1999) . All these transgenic and WT mice were genotyped from tail tip biopsies.
Data shown in Fig. 1 were obtained from young adult (8-10 week-old) male C57bl/6 mice (Charles-River, Barcelona, Spain), while to obtain embryos for cell cultures, we mated young adult C57Bl/6 mice (Charles-River).
The animals were group-housed under controlled temperature (23 ± 2 C) and subjected to a fixed 12 h light/dark cycle, with free access to food and water. We applied the principles of the ARRIVE guideline in designing and performing the in vivo and in vitro pharmacological experiments (see below), as well as for data management and interpretation. All efforts were made to reduce the number of animals used and to minimize their stress and discomfort. The animals used to perform the in vitro studies were deeply anesthetized with halothane before sacrifice (no reaction to handling or tail pinching, while still breathing).
In vitro real-time fluorescent measurement of deoxyglucose uptake in hippocampal slices
Experiments were performed as before (Lemos et al., 2015) . Five young C57bl/6 mice were sacrificed, and their brain was quickly removed and placed in ice-cold Krebs-HEPES solution (in mM: NaCl 113, KCl 3, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 2.5, NaHCO 3 25, glucose 5.5, HEPES 1.5, pH 7.2). Coronal vibratome slices (300 mm) were left to recover for 1 h at room temperature in Krebs-HEPES solution gassed with 5% CO 2 and 95% O 2 , and then gently mounted on coverslips with the hippocampus in the center, and placed in a RC-20 superfusion chamber on a PH3 platform (Warner Instruments, Harvard, UK). The slices were superfused with gassed Krebs-HEPES solution at a rate of 0.5 mL min-1 in a closed circuit, and they were then photographed with a CoolSNAP digital camera (Roper Scientific, Trenton, NJ, USA) every 30 s over the following 30 min (using a 5Â PlanNeofluar-objective [NA 0.25] on an inverted Axiovert 200 M fluorescence microscope [Carl Zeiss, Germany] , coupled to a Lambda DG-4 integrated 175 Watt light source and wavelength switching excitation system [Sutter Instrument Company, Novato, CA, USA] to allow real-time video imaging). The data was band-pass filtered for excitation (BP470/40) and emission (BP525/50).
After recording 4 images for auto-fluorescence (to establish the baseline), 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG; 30 mM) was applied through the reservoir and 15 min later, JWH133 (1 mM), GP1a (100 nM) or the DMSO vehicle alone (0.1% v/v) were administered. All measurements were obtained in duplicate from each animal (see Supplementary Fig. 1 for additional details).
Cell culture preparation
Because the embryonic hippocampus is too small to provide enough cells for our assays, neuronal and astrocyte primary cultures were prepared from the neocortex as before (Lemos et al., 2015) . The neocortex of E18 male and female C57Bl/6 rat embryos was digested for 15 min with 0.125% trypsin (type II-S, from porcine pancreas, Sigma-Aldrich Portugal) and 50 mg/mL DNAse (SigmaAldrich) in Hank's balanced salt solution without calcium and magnesium (in mM: NaCl 137, KCl 5.36, KH 2 PO 4 0.44, NaHCO 3 4.16, Na 2 HPO 4 0.34, D-glucose 5, pH 7.2). After dissociation, astrocytes were grown in plastic Petri dishes (p100) for 14 days in DMEM with 10% fetal bovine serum, 50 U/mL penicillin and 50 mg/mL streptomycin (Sigma-Aldrich), at 37 C in an atmosphere of 95%/5% air/ CO 2 , replacing half of the medium at DIV 7. The cells were then trypsinized and plated onto poly-D-lysine (100 mg/mL, SigmaAldrich) and laminin (10 mg/mL, Sigma-Aldrich) coated 24-well culture plates at a cell density of 150,000/cm 2 . Uptake assays were performed 24 h later. For neuronal cultures, cells were plated directly onto poly-D-lysine and laminin coated 24-well culture plates, at the same cell density, in DMEM plus 10% fetal bovine serum, 50 U/mL penicillin and 50 mg/mL streptomycin. Two hours after seeding, the medium was replaced by Neurobasal medium with 2% B27 supplement (GIBCO, Life technologies), 50 U/mL penicillin, 50 mg/ml streptomycin and 2 mM glutamine (SigmaAldrich), and cells were grown at 37 C in an atmosphere of 95%/5% air/CO 2 until they were used 14 days later. The medium was partially (40%) replaced every 4 days. On average, 15% of cells were found positive for glial fibrillar acidic protein immunostaining in randomly chosen wells (Lemos et al., 2015) .
In vitro 3 H-deoxyglucose uptake in neocortical neuron and astrocyte cultures
The assays were carried out according to Lemos et al. (2015) . For these assays, we used 7 different astrocyte cultures and 5 neuron cultures from 7 and 5 independent preparations (pregnant dams). After 15 days in culture, the culture medium was replaced with 250 mL Krebs-HEPES assay solution (pH 7.4; 37 C) (see above), containing either the vehicle alone (DMSO 0.1%, in half of the plate), or the CB 2 R-selective antagonist, AM630 (1 mM, in the other 12 wells). The cultures were incubated for 60 min, at 37 C, and the CB 2 R agonists JWH133 (100 nM) (4 wells/plate) or GP1a (100 nM) (4 wells/plate), or their vehicle (DMSO 4 wells/plate), was gently added to the wells in a volume of 250 mL, together with AM630 (i.e. 3 Â 4 wells/plate) or its vehicle (i.e. 3 Â 4 wells/plate), and the radioactive glucose analogue 3 H-2-deoxyglucose (  3 HDG; 16.7 nM, final concentration). After a further 30 min incubation at 37 C, the plates were transferred onto ice and the 3 H content was measured in an aliquot from each well (to assess the small differences in the individual 3 H concentration in each well that pipetting and mixing solutions may introduce). The cells were then washed gently 3 times with 1 mL ice-cold Krebs-HEPES, 300 mL NaOH (0.5 M) was added to each well, and the plates were left on a shaker for an hour to recover the proteins and In this experimental model, cytochalasin B (10 mM) largely inhibits glucose uptake in both cell cultures, thus confirming the specificity of the transport process (Lemos et al., 2015) . Additionally, the plasma membrane Na
, also inhibited neuronal glucose uptake in this assay by 42.8 ± 2.1% (n ¼ 3, P < 0.01; figure not shown).
In vitro 3 H-deoxyglucose uptake in hippocampal slices
To better characterize the glucoregulator role of CB 2 R signalling pharmacologically, we moved to an in vitro glucose uptake protocol previously optimized in acute hippocampal slices which allows the effect of various treatments to be compared simultaneously in different strains in a pairwise arrangement (Lemos et al., 2012 (Lemos et al., , 2015 . Animals were anesthetized with halothane, sacrificed (around 14:00 o'clock each experimental day to reduce potential circadian hormonal effects), and their brain was immediately placed in ice-cold Krebs-HEPES assay. The hippocampus was cut into 450 mm-thick transverse slices with the help of a McIlwain tissue chopper, and the slices were gently separated in ice-cold carboxygenated (95% O 2 and 5% CO 2 ) assay solution, and maintained at 37 C in a multichamber slice incubator with 50 ml of carboxygenated assay solution until the end of the experiment. Four slices were used from each animal and in each experimental condition. The CB 2 R-selective antagonist, AM630 or its vehicle (DMSO 0.1%) were bath-applied from min 55 of the preincubation period. WIN55212-2, JWH133, ACEA or DuP697, LY2183240, as well as JZL184 and WWL70 combined or their vehicle (DMSO 0.1%) were added from min 60 of the preincubation period, and the radioactive glucose analogue, 3 H-2-deoxy-D-glucose ( 3 HDG; final cc. 2 nM) was applied to the bath 5 min later. After 30 min, the slices were washed twice in ice-cold assay solution for 5 min and collected in 1 mL NaOH (0.5 M) to dissolve the slices. An aliquot of 800 mL was then assayed for 3 H in a Tricarb b-counter, while the remaining solution was used to quantify the protein in a bicinchoninic acid assay (Merck Biosciences, Germany). Tritium uptake was multiplied by a factor of 2.75 Â 10 6 to estimate the total glucose uptake (corresponding to the concentration difference between D-glucose and 3 HDG in the uptake medium; Lemos et al., 2012) .
Blood glucose measurements
Blood glucose from non-fasted WT and TgAPP mice was assessed before and one hour following the acute administration of JWH133 0.2 mg/kg i.p. Glucose was measured in one drop of blood Fig. 1 . Time-course and sub-regional variation of the effect of CB 2 R agonists on the uptake of the fluorescent glucose analogue, 2-NBDG in hippocampal slices of young C57Bl/6j male mice. For technical details and additional information, see Supplementary Methods, Supplementary Fig. 1 and Supplementary Video. (A,A 0 ) Representative images illustrating the distribution of the fluorescence signal, using the false color scale of blue (low signal), green (moderate signal) and yellow (strong signal). As indicated in the time-course graph (B), image (A) was taken just before the treatment (minute 15 of baseline), and image (A 0 ) was photographed close to the end of the exposure to GP1a (100 nM: see also Supplementary Video). (B) JWH133 (1 mM) and GP1a (100 nM) both increased the uptake in astrocyte-rich zones of the hippocampus. The displayed curves represent the mean þ S.E.M.
of individual net effects (in duplicate) in each animal, which was obtained after the subtraction of the respective DMSO controls (in duplicates per animal) from the raw treatment data. Therefore, the DMSO control is represented with the dashed line crossing the zero value. (C) The individual points represent the average of 2 different slices from the same mouse in duplicate (n ¼ 5): *P < 0.05 and **P < 0.01. Fig. 2 . CB 2 R activation stimulates hippocampal glucose uptake in astrocytes and neurons in vitro. The CB 2 R-selective agonists JWH133 (30 nM) and GP1a (100 nM) stimulated glucose uptake in (A) primary cortical astrocyte and (B) neuronal cultures from C57Bl/6 mice, as assessed using the 3 HDG uptake assay (30 min). The CB 2 R selective antagonist, AM630 (1 mM) prevented the action of the CB 2 R agonists, while it had no effect on the uptake per se. D-glucose uptake is expressed as mean þ SEM in nmol/mg protein (n ¼ 7 astrocyte and n ¼ 5 neuron cultures, performed in quadruplicate, at a density of 15 Â 10 4 cells/cm in 24-well plates). *P < 0.05 and **P < 0.01 vs.
DMSO control; n.s., not significant.
from the tail using Glucocard Memory meter strips (Menarini, Spain), in a range of 40e500 mg/mL.
Endocannabinoid level measurement in mouse hippocampus
Endocannabinoids were measured externally (Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen, UK). Lipid extraction was performed by homogenizing the frozen hippocampi on ice in 600 mL of acetonitrile/methanol (50/50) using an Ultra-Turrax. Upon addition of 6 pmol of N-(2-hydroxyethyl-1,1,2,2-d4)-5Z,8Z-,11Z,14Z-eicosatetraenamide [deuterated (d4)-AEA; Tocris Bioscience, UK] as an internal standard, the samples were diluted to 70% water and centrifuged. The pellets were kept for total protein determination. Solid-phase extraction (Strata-X 33 mm columns, Phenomenex) was performed before the LC/MS analysis on a Thermo Surveyor liquid chromatographic system coupled to an electrospray ionization triple quadrupole TSQ Quantum mass spectrometer operated in positive ionization mode. Chromatographic analysis was performed on an ACE 5 mm C8 (150 Â 2.1 mm, Hichrom) column and the analytes were eluted using an isocratic mobile phase of water/ methanol/formic acid (15/85/0.5 v/v/v) at a flow rate of 200 mL/min.
The column was maintained at 30 C and the sample tray at 4 C during the analysis. The extraction efficiency was >95% and the limit of quantification was 0.01 pmol for AEA and <25 pmol for 2-AG. The sample concentrations were determined from calibration curves and the endocannabinoid levels were expressed per mg protein (Bradford assay).
Endocannabinoid hydrolysis assay
Experiments were carried out as before (Mulder et al., 2011) , and adapted to mice (Pascual et al., 2014) . Cortices were mechanically homogenized in TriseHCl (20 mM, pH 7.2) containing 0.32 M sucrose and protease inhibitors, and centrifuged to eliminate nuclei and cellular debris (1000g, 10 min, 4 C). Protein concentrations were determined by Bradford's colorimetric method. The 2-AGdegrading activity was assessed by incubating sample fractions (50 mg protein) in a solution containing TriseHCl (10 mM, pH 7.2), 1 mM EDTA, fatty acid-free bovine serum albumin (1.25 mg/mL), and 3 H-2-AG in a final volume of 200 ml for 15 min at 37 C. Identical conditions were used to assess AEA degrading activity using 3 H-AEA ([1-H]ethanolamine, 25 mM, 40 Ci/mmol specific activity; ARC Inc.). Reactions were stopped by the addition of 400 mL chloroform:methanol (2:1, v/v) and vigorous vortexing, after centrifugation (2000g, 10 min, 4 C), ethanolamine or glycerol, the AEA and 2-AG hydrolysis products respectively, were obtained in the upper phase, and they were transferred into scintillation vials and radioactivity measured by liquid scintillation spectroscopy. The experimental conditions were selected from pilot experiments establishing the relationship of substrate and protein concentrations to identify optimal AEA-degrading enzymatic activity (data not shown), allowing 50% of AEA converted into ethanolamine.
Blanks were prepared identically except that the membranes were omitted or inactivated by boiling for 10 min or by the addition of chloroform:methanol (1:1, v/v) before use. No differences were observed among the different blanks. These values were subtracted Fig. 3 . CB 2 R activation stimulates glucose uptake in hippocampal slices of both middle-aged and young mice ex vivo. A) The CB 2 R-selective agonist, JWH133 (1 mM), the mixed CB 1 R/ CB 2 R agonist, WIN55212-2 (1 mM), as well as the COX-2 inhibitor, DuP697 (500 nM) all increased glucose uptake in 12-month-old wild-type (WT) C57Bl/6j mice. All these effects were prevented by a 5 min preincubation with the CB 2 R-selective antagonist, AM630 (1 mM). Inhibition of other endocannabinoid metabolizing enzymes, namely, FAAH, MAGL or a,bDH6, with LY2183240, JZL184 and WWL70 (all at 1 mM) respectively, did not affect glucose uptake. B) By contrast, only JWH133 and WIN55212-2 but not DuP697 stimulated glucose uptake in the TgAPP 2567 mice. Data represent the mean þ SEM of individual measurements from 6 to 12 animals, with the dashed line indicating the DMSO control values: *P < 0.05 vs. DMSO-treated slices; n.s., not significant. C) JWH133 (1 mM), stimulated the uptake of glucose in acute hippocampal slices of 10 week-old CB 1 R KO mice and their WT littermates. Each of the connected pairs of squares and circles represent one animal. *P < 0.05 vs. DMSO-treated slices (n ¼ 6). Fig. 4 . AEA levels were reduced in the hippocampus of TgAPP mice. Of the two principal endocannabinoids, the levels of AEA (B) but not of 2-AG (A) were significantly lower (by 38%) in the TgAPP mice (dark bars) than in the WT (light bars), as assessed by combined liquid chromatography-mass spectrometry. Data represent the mean þ SEM of individual measurements from 7 animals. 2-AG hydrolysis (C) was also unaltered in hippocampal membranes of TgAPP mice in vitro (n ¼ 6), however, AEA metabolism (D) by FAAH into ethanolamine was significantly smaller in the transgenic hippocampi in vitro (n ¼ 6). *P < 0.05, ***P < 0.001; n.s., not significant. from each enzymatic activity.
Enzyme activity was expressed as picomole [1,2,3- 
FDG-PET)
These experiments were carried out as described previously (Martín-Moreno et al., 2012) with only slight modifications. In the PET studies the images of basal (no treatment) uptake were acquired, and 4 days later the animals were injected with JWH133 0.2 mg/kg ip, and after 30 min, the radiotracer was injected and new PET images were acquired (see below).
PET images were acquired in fasted mice injected (i.p.) with 18 FDG (approx. 11.1 MBq or 300 mCi/200 ml saline, PET Technology Institute, Madrid). After a 30 min period for radiotracer uptake, the animals were anesthetized by isoflurane (2%) inhalation, to assure immobilization during the scanning process, and they were placed on the bed of the tomograph. Images of 18 FDG uptake were acquired over 30 min, immediately followed by a CT (computed tomography) acquisition (Albira ARS small animal PET/CT dual scanner, Oncovision, Spain). PET images were reconstructed using the ordered subset expectation maximization algorithm (OSEM, 3 iterations), applying corrections for dead time, radioactive decay, random coincidences and scattering. For the CT images a high resolution filtered back projection (FBP) algorithm was used.
Metabolic activity was quantified by matching the CT image of the skull of each animal to a common magnetic resonance (MR) mouse brain template, in which regions of interest were previously delineated. After saving the spatial transformation, it was applied to the corresponding fused PET image, to allow the correct coregistration of the PET image to the MR brain template. Results were normalized to the actual radioactivity dose injected and the body weight of each animal (Kuntner et al., 2009 ). All these processes were carried out with PMOD software version 3.0 (PMOD Technologies, Switzerland).
Data presentation and statistical analysis
All data are expressed as the means ± or þ SEM of the number of independent observations (n) indicated. Normalized data were tested for normality with the Kolmogorov-Smirnov normality tests and statistical significance was calculated by one sample t-test . D) Acute JWH133 injection does not alter the blood glucose levels in the two strains and hence, JWH133 does not appear to influence glucose uptake in the brain through systemic mechanisms. E-G 0 ) Before-after graphs summarizing the basal uptake, and 4 days later, the JWH133-stimulated (JWH) uptake in the frontal E, E 0 ) and temporal F, F 0 ) cortices, as well as in the hippocampus G, G 0 ), of 4 wild-type (WT, E-G) and 4 TgAPP 2567 (E 0 -G 0 ) mice. Uptake values were corrected for the dose injected and for body weight, *P < 0.05.
against the hypothetical value of zero (Figs. 1C and 2 ). Alternatively, a paired t-test (Fig. 3C ) or repeated measures of ANOVA followed by Bonferroni's post-hoc test were used, and a value of P < 0.05 was accepted as significant.
Results
CB 2 R activation rapidly enhances glucose uptake in hippocampal slices
First we assessed whether CB 2 R activation affects glucose uptake in superfused hippocampal slices, and the rate of fluorescencelabeled deoxyglucose (2-NBDG) accumulation was tested at 30 s resolution in such slices. The basal accumulation of 2-NBDG was most evident in astrocyte-rich areas of transverse hippocampal slices, i.e. in the in the stratum lacunosum, followed by the strata radiatum and moleculare, and the smallest signal was found in the strata pyramidale and granulare (Fig. 1AeA 0 ) , consistent with previous findings (Jakoby et al., 2014) . Importantly, both of the two selective CB 2 R agonists, GP1a (100 nM, P < 0.01) and JWH133 (1 mM, P < 0.05), rapidly increased the velocity of 2-NBDG accumulation in these hippocampal slices ( Fig. 1 B,C , and Supplementary Video).
Supplementary data related to this article can be found online at http://dx.doi.org/10.1016/j.neuropharm.2016.03.015.
CB 2 R activation stimulates glucose transport in cultured neurons and astrocytes
Since the use of 2-NBDG underrepresents neuronal glucose transport (Jakoby et al., 2014) , we measured the effect of acute in vitro CB 2 R activation on glucose uptake by primary mouse cortical astrocytes and neurons using a 3 HDG transport assay. In the presence of JWH133 (30 nM) over 30 min, glucose uptake augmented by 35.4 ± 7.5% in astrocytes (n ¼ 7, P < 0.01 vs. DMSO control) and by 13.5 ± 4.0% in neurons (n ¼ 5, P < 0.05: 2 A,B).
Notably, JWH133 exhibits an EC 50 value close to 1 mM at the CB 1 R (Huffman et al., 1999) . To avoid the possible non-specific co-activation of CB 1 R in these cell cultures, we opted for testing JWH133 here at 30 nM, i.e. 9-times above its EC 50 at the CB 2 R but more than an order of magnitude below its EC 50 at the CB 1 R (Huffman et al., 1999) . Similarly, GP1a at a concentration~2700-times above its EC 50 at the CB 2 R but~4-fold below its EC 50 at the CB 1 R, i.e. at 100 nM (Murineddu et al., 2006 ) also increased glucose uptake in astrocytes by 22.4 ± 10.7% (n ¼ 7, P < 0.05) and by 13.7 ± 2.4% in neurons (n ¼ 5, P < 0.01: Fig. 2 A,B) . Therefore, with the chosen ligand concentrations we achieved good selectivity toward the CB 2 R while still observing maximal effect amplitudes. The CB 2 R antagonist AM630 (1 mM) did not alter glucose uptake per se in cultures of astrocytes (n ¼ 7) or neurons (n ¼ 5). However, in the presence of AM630, neither GP1a nor JWH133 significantly altered glucose uptake in either of these two cell types (P > 0.05 vs. AM630 control; astrocytes n ¼ 5, neurons n ¼ 4: Fig. 2 A,B) . In summary, CB 2 R activation was more effective at increasing glucose uptake in astrocytes compared with neurons. As stated previously, our neuron cultures contained 15% of astrocytes, which likely contributed to the effect of the CB 2 R agonists. However, this low astrocytic contamination cannot solely account for the effect amplitudes observed neuronal cultures.
b-amyloidosis hinders endogenous CB 2 R activation
A similar pharmacological analysis was then performed in hippocampal slices of 12-month-old TgAPP mice and their agematched controls. The normalized control uptake values of the TgAPP hippocampus amounted to 105.4 ± 8.9% of the WT control uptake (i.e. þ5.4 ± 8.9% over DMSO control) when assessed in a pairwise arrangement (n ¼ 19 pairs, P > 0.05: Fig. 3 A,B) . Glucose uptake was significantly enhanced by the CB 2 R-selective agonist JWH133 (1 mM) in both the WT (þ26.3 ± 10.0%, n ¼ 12, P < 0.05: Fig. 3A ) and the TgAPP slices (þ16.7 ± 6.7%, n ¼ 12, P < 0.05: Fig. 3B ). Due to the limited availability of 12-month old TgAPP mice, we made a risk-free decision when testing JWH133 at 1 mM, i.e. at the maximal concentration where good CB 2 R-selectivity is still achieved (Huffman et al., 1999) .
Importantly, glucose uptake was also stimulated by the nonselective ("mixed") CB 1 R/CB 2 R agonist, WIN55212-2 (1 mM), in both WT (þ22.4 ± 9.2%, n ¼ 12, P < 0.05: Fig. 3A ) and TgAPP slices (þ17.5 ± 7.1%, n ¼ 12, P < 0.05: Fig. 3B ). While the selective CB 2 R antagonist, AM630 (1 mM) had no effect on glucose uptake per se in either strain (n ¼ 12), it did prevent JWH133 and WIN55212-2 from stimulating glucose uptake in both WT and TgAPP slices (n ¼ 6: Fig. 3 A,B) . Cannabinoid agonists exert their actions predominantly via CB 1 R activation in the mammalian brain (Katona and Freund, 2012) . To check if CB 1 Rs are also involved in the stimulation of glucose uptake, first we tested the CB 1 R-selective agonist ACEA at a concentration half way between its K d values at the CB 1 R and the CB 2 R, i.e. at 1 mM (Hillard et al., 1999) . ACEA did not affect glucose uptake in the middle-aged C57Bl/6 mice (þ5.3 ± 7.9%, n ¼ 7, P > 0.05: Fig. 3A ). Subsequently, we asked if CB 1 Rs were involved in the effect of JWH133, taken that this ligand has some affinity toward the CB 1 R at 1 mM (Huffman et al., 1999 ). Thus, we tested JWH133 (1 mM) in acute hippocampal slices of young adult CB 1 R KO mice and their WT littermates on the CD-1 strain. JWH133 (1 mM) significantly stimulated glucose uptake þ13.4 ± 3.7% (n ¼ 6, P < 0.05) in the WT mice and þ26.7 ± 9.0% (n ¼ 6, P < 0.05) in the CB 1 R KO, thus virtually, JWH133 was more twice as more effective in the absence of the CB 1 R. These data together with the results with ACEA also confirm the absence of acute modulation of hippocampal glucose uptake by CB 1 Rs.
Next, we assessed whether endogenous activation of CB 2 R by the major endocannabinoids, AEA and 2-AG also bolstered glucose uptake. To that end, we inhibited either fatty acid amide hydrolase (FAAH) or cyclooxygenase-2 (COX-2), two enzymes known to be involved in AEA degradation (Egertov a et al., 2003; Fowler et al., 2013) . The treatment of slices with DuP697 (500 nM), a selective COX-2 inhibitor (IC 50 at COX-2, 10 nM; IC 50 at COX-1, 800 nM; Gierse et al., 1995) , augmented glucose uptake by þ16.6 ± 7.7% in the WT mice (n ¼ 6, P < 0.05: Fig. 3A ) -an effect that was prevented by CB 2 R blockade (n ¼ 6: Fig. 3A) . However, unlike in the WT, DuP697 failed to modify glucose uptake in the TgAPP mice (n ¼ 6, Fig. 3B ). In contrast, LY2183240 (100 nM), a potent dual inhibitor of FAAH and AEA reuptake (Nicolussi et al., 2014) , did not affect glucose uptake in WT mice, and therefore, it was not tested in TgAPP mice slices. The major enzymes that degrade 2-AG in the mammalian brain are monoacylglycerol lipase (MAGL) and a/bhydrolase domain 6/12 (ABDH6/12) (Savinainen et al., 2012; Murataeva et al., 2014) . The inhibition of 2-AG hydrolysis by the concurrent application of JZL184 (1 mM), a MAGL inhibitor (Long et al., 2009) , and WWL70 (1 mM), an a,bDH6/12 inhibitor (Li et al., 2007) , also failed to modify glucose uptake in WT mice (Fig. 3 A) .
Lower AEA levels in the hippocampus of TgAPP mice
The inability of COX-2 inhibition to stimulate glucose uptake in a CB 2 R-dependent fashion in the TgAPP hippocampus suggests a loss of endocannabinoid function, which prompted us to measure endocannabinoid levels in these two strains. The hippocampal levels of AEA and 2-AG in the WT mice (Fig. 4) were similar to those reported in the rat brain (Stella et al., 1997) , and while no difference in the 2-AG levels were detected between WT and TgAPP mice (n ¼ 7, P > 0.05), AEA levels in the latter were 37.8 ± 11.4% lower than in WT (n ¼ 7, P < 0.05) (Fig. 4A,B) . Accordingly, there was a 2.4 ± 0.3 fold increase in the 2-AG/AEA ratio in TgAPP mice (n ¼ 7, P < 0.001). The degradation of 2-AG was also not statistically different between the WT and TgAPP (n ¼ 6, P > 0.05) (Fig. 4D) . Interestingly, the degradation of AEA into ethanolamine by FAAH was significantly reduced in TgAPP by 33.5 ± 8.9% (n ¼ 6, P < 0.001) (Fig. 4D). 3.5. Effect of CB 2 R activation on 18 FDG uptake e a PET analysis in vivo Finally, we tested the feasibility of targeting CB 2 R to stimulate brain glucose uptake in middle-aged mice in vivo. We first evaluated the basal uptake of 18 FDG in the brain regions typically bearing the hallmarks of the diminished 18 FDG signal in the Alzheimer's disease-affected human brain, i.e. the frontal and temporal cortices, and the hippocampus (Mosconi, 2005) . Like the ex vivo data, we observed no difference in the 18 FDG signal in the aforementioned areas of WT and TgAPP mice (n ¼ 9: Fig. 5 A,A 0 ,B,B 0 ,C). Four days later, the same animals were injected with a small dose of JWH133 (0.2 mg/kg, i.p.) and they were re-evaluated for 18 FDG uptake.
While this CB 2 R agonist did not alter blood glucose levels (Fig. 5 D) , it did stimulate glucose uptake by an average of 31.5% in each of the three regions in the WT mice (n ¼ 4, P < 0.05: Fig. 5EeG ), as well as by an average of 21.3% in the TgAPP mice (n ¼ 4, P < 0.05: Fig. 5E 0 eG 0 ).
Discussion
4.1. A novel role for cannabinoid CB 2 receptors: stimulating glucose uptake in the brain
We show here that CB 2 R activation in vitro, and more importantly, in vivo rapidly enhances cerebral glucose uptake by~30% over the basal levels. These data are in concert with a recent finding that the intraperitoneal injection of the mixed CB 1 R/CB 2 R agonist, HU210 increased cerebral 18 FDG PET signal by 21% in the rat (Nguyen et al., 2012) . Since CB 1 R activation decreases mitochondrial glucose metabolism (Duarte et al., 2012 ) CB 2 Rs are likely involved in the stimulation of brain metabolism in the above study. These data support the view of the recently described antagonistic interaction between CB 1 Rs and CB 2 R in neurons (Call en et al., 2012) . Given that brain glucose availability controls cognition and memory in humans (Messier, 2004) and that central metabolic boosting alleviates the cognitive symptoms of dementia, these data suggest that CB 2 R agonists might represent a novel class of nootropic drugs (Branconnier, 1983) . This raises the interesting hypothesis that by promoting AEA release, neural activity can activate central CB 2 Rs and thereby refuel circuits under heavy load. Indeed, it was recently found that JWH133 enhanced aversive memory consolidation in mice, while the genetic ablation or pharmacological inhibition of CB 2 R impaired it (García-Guti errez et al., 2013).
2-NBDG uptake in slices suggested a contribution of astrocytes in the effects of CB 2 R activation. Consistent with this, our data in cultures show that CB 2 R influences both astrocytic and neuronal glucoregulation. CB 2 R are found at low density on most cell types in the brain, including activated microglia and astrocytes controlling neuroinflammation (Ramírez et al., 2005; Martín-Moreno et al., 2012) , and inhibiting astrocytoma growth (S anchez et al., 2001 ). Moreover, CB 2 R mRNA or protein has also been found in several types of neurons, including cortical, hippocampal and midbrain neurons (Atwood and Mackie, 2010; Call en et al., 2012; Den Boon et al., 2012; Zhang et al., 2014) . Interestingly, CB 2 R expression and density in neurons apparently surpasses that in microglia or astrocytes in the mouse neocortex (Savonenko et al., 2015) and hippocampus (Li and Kim, 2015) .
The therapeutic activation of CB 2 R is safe and it does not trigger psychoactivity (Atwood and Mackie, 2010; Pertwee, 2012) . Furthermore, CB 2 R density is known to increase in Alzheimer's disease and Down's syndrome, as well as in b-amyloidosis in vitro (Esposito et al., 2007; Ruiz-Valdepeñas et al., 2010; Solas et al., 2013) . This probably reflects an adaptive self-defense process since CB 2 R activation confers neuroprotection in several experimental models of Alzheimer's disease (Ramírez et al., 2005; Esposito et al., 2007; Ruiz-Valdepeñas et al., 2010; Martín-Moreno et al., 2012) .
AEA and b-amyloidosis
The first step in common pathomechanisms toward AD pathology is excessive b-amyloid accumulation (Sperling et al., 2013; Zahs and Ashe, 2013) . Remarkably, the antagonistic relationship between AEA and b-amyloid appears to be bi-directional: b-amyloid toxicity is prevented by AEA in human cell lines in vitro (Milton, 2002 ) and conversely, b-amyloid treatment decreases AEA levels in C6 rat astroglioma cells (Esposito et al., 2007) . Accordingly, AEA levels decrease in the AD brain and they are inversely correlated with b-amyloid levels (Jung et al., 2012) , consistent with the lower hippocampal AEA levels in TgAPP mice. b-amyloidosis may lower AEA levels by either bolstering catabolism and/or by impairing its synthesis. COX-2 is an important enzyme in AEA metabolism (Glaser and Kaczocha, 2010; Pamplona et al., 2010) , furthermore, bamyloidosis induces COX-2 expression in astrocytes (Giovannini et al., 2002) and in AD-affected neurons. Hence, COX-2 inhibition may help to decrease the incidence or slow the progress of AD (Berk et al., 2013) . In fact, in a previous work we treated TgAPP 2576 mice orally for four months with the CB 2 R-selective agonist JWH133 and we observed an attenuation of the AD phenotype, including recovery from memory impairment and neuroinflammation, as well as a normalization of the increase in COX-2 protein levels (Martín-Moreno et al., 2012) . Strikingly, COX-2 inhibition by the selective DuP697 antagonist facilitated glucose uptake via CB 2 R activation in WT but not in the TgAPP mice, probably due to the rescue of AEA from COX-2-driven tonic metabolism in WT mice (Glaser and Kaczocha, 2010; Pamplona et al., 2010) . In the TgAPP mice, we found a 38% decrease of AEA, suggesting that these levels were already too low to stimulate the CB 2 Rs, even following COX-2 blockade. In fact, this may illustrate a deficit in synthesis, since AEA production requires the concurrent stimulation of both NMDA and acetylcholine receptors (Stella and Piomelli, 2001) , both of which become hypofunctional in AD (Pavía et al., 1998; Giovannini et al., 2002) . In the present work FAAH activity was reduced in TgAPP mice, as judged by the decrease in AEA hydrolysis, again in agreement with its reduction in AD brain, which we recently reported (Mulder et al., 2011; Pascual et al., 2014) . This reduction is mimicked by pathologically relevant Ab 1-40 peptide concentrations (Pascual et al., 2014) and may serve as to preserve AEA levels under lower AEA production, as a compensatory mechanism. Even though, FAAH inhibition did not stimulate glucose uptake, suggesting that AEA metabolism by FAAH is not a rate limiting factor for CB 2 R activation in the WT hippocampus.
Cannabinoid receptors and glucose uptake
Although the role of cannabinoid receptors in peripheral glucoregulation is extensively studied (Matias et al., 2008) , the mechanism through which CB 2 R activation facilitates glucose transport in the brain awaits further interrogation. Several mechanisms could be invoked on that respect. For instance, cannabinoids stimulate AMP-activated protein kinase (Dagon et al., 2007) , a major intracellular energy sensor, which leads to enhanced glucose uptake by stimulating glucose transporter (GLUT) membrane expression and transport efficiency (Rutter et al., 2003; Weisov a et al., 2009 ). More importantly, the effect was absent in CB 2 R knockout mice (Dagon et al., 2007) . A possible direct effect of CB 2 R agonists on glucose transporters remains unexplored. New synthesis of transporters would not parallel the acute pharmacological effects reported here. Therefore, we suggest that CB 2 R agonists may favor transporter localization at the plasma membrane. On the other hand, it is less likely that CB 2 Rs increased glucose uptake driven by the stimulation of its metabolism, because we found previously that WIN55212-2 slows rather than facilitates the mitochondrial oxidative metabolism of glucose via CB 1 R activation both in neurons and astrocytes (Duarte et al., 2012) .
Conclusions
In summary, the present results provide the first direct pharmacological evidence in vitro and in vivo of a role of CB 2 R in central glucoregulation. Additionally, we found that glucoregulation by endogenous CB 2 R signalling is negatively affected by b-amyloidosis, thought to be the first pathological step in AD. Therefore, it would be interesting to perform further studies to define how CB 2 R mediated glucoregulation contributes to the recently discovered therapeutic potential of CB 2 R agonists in animal models of AD (Martín-Moreno et al., 2012; Wu et al., 2013; Aso and Ferrer, 2014; Cheng et al., 2014) .
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